Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18–49 years of age

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

(2020) Brian J Ward et al.   LANCET

Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility

(2019) Nicholas C. Wu et al.   Cell Host & Microbe

A Tale of Two Mutations: Beginning to Understand the Problems with Egg-Based Influenza Vaccines?

(2019) Kanta Subbarao et al.   Cell Host & Microbe

Challenges in the development of egg-independent vaccines for influenza

(2019) Claudia Maria Trombetta et al.   Expert Review of Vaccines

Role of Egg-adaptation Mutations in Low Influenza A(H3N2) Vaccine Effectiveness During the 2012–2013 Season

(2018) Danuta M Skowronski et al.   CLINICAL INFECTIOUS DISEASES

The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?

(2018) Brian J. Ward et al.   Human Vaccines & Immunotherapeutics

Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age

(2017) Lisa M Dunkle et al.   JOURNAL OF INFECTIOUS DISEASES

Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains

(2017) Seth J. Zost et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Plant-Made Vaccines in the Fight Against Cancer

(2017) Alejandra Wong-Arce et al.   TRENDS IN BIOTECHNOLOGY

Edible plants for oral delivery of biopharmaceuticals

(2016) Matilde Merlin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults

(2016) Stéphane Pillet et al.   CLINICAL IMMUNOLOGY

Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses

(2016) Danuta M Skowronski et al.   Eurosurveillance

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study

(2016) Stephan Bart et al.   Human Vaccines & Immunotherapeutics

Bringing plant-based veterinary vaccines to market: Managing regulatory and commercial hurdles

(2015) Jacqueline MacDonald et al.   BIOTECHNOLOGY ADVANCES

Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story

(2015) Tsafrir S. Mor   BIOTECHNOLOGY LETTERS

Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens

(2014) Nathalie Landry et al.   CLINICAL IMMUNOLOGY

Low 2012–13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses

(2014) Danuta M. Skowronski et al.   PLoS One

Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines

(2014) Brian J. Ward et al.   VACCINE

Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines

(2013) Sabine Nakowitsch et al.   Biotechnology Journal

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age

(2013) Geoffrey J. Gorse et al.   VACCINE

Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza

(2010) Nathalie Landry et al.   PLoS One

The production of biopharmaceuticals in plant systems

(2009) Saskia R. Karg et al.   BIOTECHNOLOGY ADVANCES

Plants as biofactories

(2008) Vadim Mett et al.   BIOLOGICALS

Influenza virus-like particles produced by transient expression inNicotiana benthamianainduce a protective immune response against a lethal viral challenge in mice

(2008) Marc-André D’Aoust et al.   PLANT BIOTECHNOLOGY JOURNAL

Stabilizing the glycosylation pattern of influenza B hemagglutinin following adaptation to growth in eggs

(2007) Zhongying Chen et al.   VACCINE